ArticleFrontiers in human neuroscience2022
Transcranial Magnetic Stimulation for Long-Term Smoking Cessation: Preliminary Examination of Delay Discounting as a Therapeutic Target and the Effects of Intensity and Duration.
Article in Frontiers in human neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03865472 (Enhancing Relapse Prevention With rTMS), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enhancing Relapse Prevention With rTMS: Dose-Response Parameters for Smoking Cessation
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Comparing neuromodulation targets to reduce cigarette craving and withdrawal: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- A preliminary randomized controlled trial of repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex in treatment seeking participants with cannabis use disorder.Drug and alcohol dependence · 2024Trial
- Determinants of Repetitive Transcranial Magnetic Stimulation Efficacy in Tobacco Use Disorder: A Pre-Registered Study.medRxiv : the preprint server for health sciences · 2026Article
- Behavioral and Functional Neuroimaging Effects of Delivering a Course of Repetitive Transcranial Magnetic Stimulation to Personalized Targets Within the Ventrolateral Or Dorsolateral Prefrontal Cortex in Treatment-Seeking Participants with Cannabis Use Disorder.medRxiv : the preprint server for health sciences · 2026Article
- Transcranial Magnetic Stimulation in Smoking Cessation: A Narrative Review of Neurobiological Mechanisms from Craving Modulation to Neural Circuit Restoration.Brain sciences · 2026Review
- Repetitive transcranial magnetic stimulation reduces smoking cravings by decreasing cerebral blood flow in the dorsolateral prefrontal cortex.Brain communications · 2025Article
- Silver Spike Point Therapy in smoking cessation: What is it and does it work?Saudi medical journal · 2023Review
- Perceived research burden of a novel therapeutic intervention: A study of transcranial magnetic stimulation for smoking cessation.Frontiers in rehabilitation sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Background: Repetitive transcranial magnetic stimulation (rTMS) is a novel treatment for smoking cessation and delay discounting rate is novel therapeutic target. Research to determine optimal therapeutic targets and dosing parameters for long-term smoking cessation is needed. Due to potential biases and confounds introduced by the COVID-19 pandemic, we report preliminary results from an ongoing study among participants who reached study end prior to the pandemic. Methods: In a 3 × 2 randomized factorial design, participants ( Results: A large effect size was found for Duration and a medium for Intensity for latency to relapse. Increasing Duration increased the odds of abstinence 7-8-fold while increasing Intensity doubled the odds of abstinence. A large effect size was found for Duration, a small for Intensity for delay discounting rate. Increasing Duration and Intensity had a small effect on participant burden. Conclusion: Findings provide preliminary support for delay discounting as a therapeutic target and for increasing Duration and Intensity to achieve larger effect sizes for long-term smoking cessation and will provide a pre-pandemic comparison for data collected during the pandemic. Clinical Trial Registration: [www.ClinicalTrials.gov], identifier [NCT03865472].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.